KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested Capital

AbCellera Biologics (ABCL) Operating Margin (2020 - 2023)

AbCellera Biologics' Operating Margin history spans 4 years, with the latest figure at 719.61% for Q4 2023.

  • For the quarter ending Q4 2023, Operating Margin fell 54427.0% year-over-year to 719.61%, compared with a TTM value of 623.8% through Dec 2023, down 66840.0%, and an annual FY2024 reading of 1091.69%, down 46787.0% over the prior year.
  • Operating Margin for Q4 2023 was 719.61% at AbCellera Biologics, up from 831.79% in the prior quarter.
  • The five-year high for Operating Margin was 77.97% in Q1 2021, with the low at 831.79% in Q3 2023.
  • Average Operating Margin over 4 years is 192.1%, with a median of 22.16% recorded in 2020.
  • Year-over-year, Operating Margin surged 54731bps in 2022 and then tumbled -86901bps in 2023.
  • Tracing ABCL's Operating Margin over 4 years: stood at 77.33% in 2020, then fell by -24bps to 58.53% in 2021, then crashed by -400bps to 175.34% in 2022, then tumbled by -310bps to 719.61% in 2023.
  • Per Business Quant, the three most recent readings for ABCL's Operating Margin are 719.61% (Q4 2023), 831.79% (Q3 2023), and 511.03% (Q2 2023).